【摘要】 经皮冠状动脉介入治疗(PCI)是冠状动脉粥样硬化的常用治疗手段。支架内再狭窄(ISR)是植入支架后较为高发的并发症。微RNA(microRNA，miRNA)可以作为再狭窄诊断和治疗的生物标志物和靶标，预防或减少再狭窄的发生。本文综述了ISR的病理生理机制，介绍了几种miRNA在ISR的功能和调节过程，阐释了其在调控血管平滑肌细胞(VSMC)和内皮细胞(EC)的表型、增殖和迁移中的作用。为针对miRNA的ISR的治疗和预防策略提出临床参考，从而指导治疗方案。

    【关键词】 微RNA 支架内再狭窄 内皮细胞 血管平滑肌细胞 经皮冠状动脉介入治疗

    The Role and Mechanisms of microRNA in In-stent Restenosis/LIU Xingjian， WANG Jinhang， ZHANG Bolun， LIU Rundong， WANG Chuan. //Medical Innovation of China， 2024， 21(27)： -188

    [Abstract] Percutaneous coronary intervention (PCI) is a common treatment for coronary atherosclerosis. In-stent restenosis (ISR) is a relatively frequent complication following stent implantation. MicroRNA (miRNA) can serve as biomarkers and targets for the diagnosis and treatment of restenosis， potentially preventing or reducing its occurrence. This article reviews the pathophysiological mechanisms of ISR， presents the functions and regulatory processes of several miRNA in ISR， and elucidates their roles in regulating the phenotypes， proliferation， and migration of vascular smooth muscle cells (VSMC) and endothelial cells (EC). This article offers clinical insights into miRNA targeted therapeutic and preventive strategies for ISR ......